W
Werner Steimer
Researcher at Technische Universität München
Publications - 61
Citations - 2706
Werner Steimer is an academic researcher from Technische Universität München. The author has contributed to research in topics: Therapeutic drug monitoring & Pharmacogenetics. The author has an hindex of 24, co-authored 59 publications receiving 2188 citations. Previous affiliations of Werner Steimer include Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Christoph Hiemke,Niels Bergemann,Hans-Willi Clement,Andreas Conca,Jürgen Deckert,Katharina Domschke,Gabriel Eckermann,Karin Egberts,Manfred Gerlach,Christine Greiner,Gerhard Gründer,E Haen,Ursula Havemann-Reinecke,Gudrun Hefner,Renate Helmer,Ger Janssen,Eveline Jaquenoud,Gerd Laux,Thomas Messer,Rainald Mössner,Matthias J. Müller,Michael Paulzen,Bruno Pfuhlmann,P. Riederer,Alois Saria,Bernd Schoppek,Georgios Schoretsanitis,Markus J. Schwarz,M. Silva Gracia,Benedikt Stegmann,Werner Steimer,Julia C. Stingl,Manfred Uhr,S. Ulrich,Stefan Unterecker,R. Waschgler,Gerald Zernig,Gabriele Zurek,Pierre Baumann +38 more
TL;DR: Following the new guidelines for therapeutic drug monitoring in psychiatry holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.
Journal ArticleDOI
Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy
Werner Steimer,Konstanze Zöpf,Silvia von Amelunxen,Herbert Pfeiffer,Julia Bachofer,Johannes Popp,Barbara Messner,Werner Kissling,Stefan Leucht +8 more
TL;DR: Combined pharmacogenetic testing for CYP2D6 and CYP1D6 genotypes identifies patients with low risk for side effects in amitriptyline therapy and could possibly be used to individualize antidepressive regimens and reduce treatment cost.
Journal ArticleDOI
Performance and Specificity of Monoclonal Immunoassays for Cyclosporine Monitoring: How Specific Is Specific?
TL;DR: Because assay bias cannot be predicted in individual samples, substantially erratic CsA dosing can result and the specificity of CsSA assays for parent C sA remains a major concern.
Journal ArticleDOI
Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Werner Steimer,Konstanze Zöpf,Silvia von Amelunxen,Herbert Pfeiffer,Julia Bachofer,Johannes Popp,Barbara Messner,Werner Kissling,Stefan Leucht +8 more
TL;DR: AT and NT concentrations can be predicted within the group of CYP2D6 extensive metabolizers, and the ASCOC provides substantial advantages compared with current methods of analysis.
Journal ArticleDOI
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
TL;DR: The data suggest that the CYP1A2*1F/*1F genotypes may be useful for clinical treatment decisions given the fact that olanzapine serum concentrations correlated with treatment response, and side effects and weight gain seem to be more influenced by serotonergic polymorphisms.